• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Rare Diseases

    EMA CHMP Backs X4`s Mavorixafor Approval for EU WHIM Syndrome

    GLOBENEWSWIRE

    Norgine Gets Positive CHMP Opinion for Mavorixafor in EU

    PR NEWSWIRE

    X4 Pharmaceuticals Presents Positive Phase 2 Trial Data at EHA

    GLOBENEWSWIRE

    X4 Pharmaceuticals Granted Fast Track for Mavorixafor by FDA

    GLOBENEWSWIRE

    X4 Pharmaceuticals to Present Phase 2 Trial Data at EHA Congress

    GLOBENEWSWIRE

    X4 Pharmaceuticals to Report Q1 2025 Results, Host Call on May 1

    GLOBENEWSWIRE

    X4 Pharmaceuticals Announces Reverse Stock Split

    GLOBENEWSWIRE

    X4 Pharma Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Norgine acquires Theravia to boost rare disease portfolio

    PR NEWSWIRE

    X4, Taiba Rare Ink XOLREMDI Deal For WHIM Syndrome In Middle East

    GLOBENEWSWIRE

    X4 Pharma`s Restructure for Mavorixafor in Chronic Neutropenia

    GLOBENEWSWIRE

    X4 Pharma Announces Inducement Grants Under NasdaqLR 5635(c)(4)

    GLOBENEWSWIRE

    X4 Pharma’s Mavorixafor MAA Validated By EMA For WHIM Syndrome

    GLOBENEWSWIRE

    X4 Pharma to Participate in Piper Sandler Healthcare Conference

    GLOBENEWSWIRE

    X4 Pharma Reports Positive Phase 2 Results in Chronic Neutropenia

    GLOBENEWSWIRE

    X4 Pharma Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    X4 Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule

    GLOBENEWSWIRE

    X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

    GLOBENEWSWIRE

    X4 Pharmaceuticals Announces Inducement Grants

    GLOBENEWSWIRE

    Orchestra BioMed Appoints John Mack To Board Of Directors

    GLOBENEWSWIRE

    X4 enters commercial fold with FDA approval of rare disease drug Xolremdi

    FIERCE PHARMA

    PANTHERx® Rare Partnering with X4 for XOLREMDI™ Distribution

    PR NEWSWIRE

    X4 Pharma to Report Clinical Biomarker Data X4P-001 at the Upcoming 2018 (AACR)

    PRESS RELEASE

    X4 Presents Data from Ongoing Ph2 Study Demo Promising Activity of X4P-001-RD

    PRESS RELEASE

    X4 Pharmaceuticals Secures $27 Million in Series B Financing

    PRESS RELEASE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.